Exploring the Elongation of Very Long Chain Fatty Acids Protein (ELOVL): A Promising Drug Target and Biomarker

Target Name: Elongation of very long chain fatty acids protein

NCBI ID: P11335

Elongation of very long chain fatty acids protein

Other Name(s): ELOVL

Exploring the Elongation of Very Long Chain Fatty Acids Protein (ELOVL): A Promising Drug Target and Biomarker

Introduction

Fatty acids are essential nutrients that play a crucial role in various physiological processes in the human body. Among the various types of fatty acids, very long chain fatty acids (VLFACs) are particularly interest-ing due to their unique structure and biological activity. VLFACs are composed of 12 to 20 carbon atoms and are primarily derived from the omega-3 and omega-6 fatty acid chains. The majority of VLFACs are pro-inflammatory, and their levels have been linked to various diseases, including cardiovascular, neurodegenerative, and autoimmune disorders.

The Elongation of Very Long Chain Fatty Acids Protein (ELOVL) is a protein that is specifically interested in due to its unique structure and function. ELOVL is a 19 kDa protein that is derived from the VLFACs. It has been shown to have anti-inflammatory and pro-resolving effects on various cellular and animal models of inflammation.

ELOVL's unique structure allows it to interact with various cellular components, including intracellular signaling pathways, cytoskeletal structures, and membrane receptors. Its anti-inflammatory properties are thought to be due to its ability to modulate the activity of various signaling pathways, including TLRs, NF -kappa-B, and the PI3K/AKT signaling pathway.

Despite the potential therapeutic benefits of ELOVL, much of its biology remains unexplored. One of the main challenges in studying ELOVL is its complex cellular localization and interactions. However, recent studies have provided new insights into the elongation of very long chain fatty acids and its potential as a drug target.

ELOVL's Localization and Interactions

ELOVL is a cytoplasmic protein, which means that it is primarily located within the cytoplasm of cells. It has been shown to localize to various cellular organelles, including the endoplasmic reticulum (ER), the mitochondria, and the endoplasmic cytoplasm (EC).

ELOVL has been shown to interact with various cellular components, including intracellular signaling pathways, cytoskeletal structures, and membrane receptors. Its localization to these components suggests that it plays an important role in the regulation of cellular processes, including inflammation and stress responses.

One of the most interesting interactions of ELOVL is its interaction with the cytoskeleton. ELOVL has been shown to interact with microtubules and act as a disruptor of the microtubule dynamics. This interaction suggests that ELOVL may have a role in the regulation of cell division and cytoskeletal organization.

ELOVL's Role in Inflammation and Stress

ELOVL has been shown to have anti-inflammatory and pro-resolving effects on various cellular and animal models of inflammation. Its unique structure and function make it an attractive target for new therapies.

In Yongrong Hui

ELOVL has been shown to have anti-inflammatory effects by modulating the activity of various signaling pathways, including TLRs, NF-kappa-B, and the PI3K/AKT signaling pathway. It has been shown to reduce the expression of pro-inflammatory genes, such as iNOS, IL-1尾, and TNF-伪, and increase the expression of anti-inflammatory genes, such as IL-10 and IL-18.

ELOVL has also been shown to have pro-resolving effects by modulating the activity of various signaling pathways, including the production of reactive oxygen species (ROS) and the activation of caspases. These effects have been shown to result in the reduction of cellular stress and the inhibition of cell death.

Conclusion

ELOVL is a unique protein that has been shown to have anti-inflammatory and pro-resolving effects on various cellular and animal models of inflammation. Its unique structure and function make it an attractive target for new therapies. Further studies are needed to fully understand the biology of ELOVL and its potential as a drug

Protein Name: Elongation Of Very Long Chain Fatty Acids Protein (nonspecified Subtype)

The "Elongation of very long chain fatty acids protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Elongation of very long chain fatty acids protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets